WO2001027123A1 - Chromium-histidine complexes as nutrient supplements - Google Patents

Chromium-histidine complexes as nutrient supplements Download PDF

Info

Publication number
WO2001027123A1
WO2001027123A1 PCT/US2000/027727 US0027727W WO0127123A1 WO 2001027123 A1 WO2001027123 A1 WO 2001027123A1 US 0027727 W US0027727 W US 0027727W WO 0127123 A1 WO0127123 A1 WO 0127123A1
Authority
WO
WIPO (PCT)
Prior art keywords
chromium
histidine
complex
absorption
diabetes
Prior art date
Application number
PCT/US2000/027727
Other languages
French (fr)
Inventor
Richard A. Anderson
Marilyn M. Polansky
Noella A. Bryden
Original Assignee
THE UNITED STATES OF AMERICA, represented by TH E SECRETARY OF AGRICULTURE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THE UNITED STATES OF AMERICA, represented by TH E SECRETARY OF AGRICULTURE filed Critical THE UNITED STATES OF AMERICA, represented by TH E SECRETARY OF AGRICULTURE
Priority to EP00970641A priority Critical patent/EP1235835B1/en
Priority to CA002386790A priority patent/CA2386790C/en
Priority to JP2001530341A priority patent/JP4837214B2/en
Priority to DK00970641T priority patent/DK1235835T3/en
Priority to DE60032509T priority patent/DE60032509T2/en
Priority to AU79990/00A priority patent/AU779042B2/en
Priority to MXPA02003459A priority patent/MXPA02003459A/en
Publication of WO2001027123A1 publication Critical patent/WO2001027123A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A23L33/165—Complexes or chelates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Chromium a physiologically important metal, is an essential element required for normal carbohydrate and lipid metabolism. Insufficient amounts may result in improper functioning of the metabolic process and lead to a number of physiological disorders . Membranes of the absorptive cells of the mammalian intestine often present a barrier to effective absorption of chromium, leading to insufficient amounts present in the bloodstream.
  • the present invention relates to a chromium complex having improved absorption capabilities .
  • Chromium also improves insulin function by increasing insulin binding to cells, insulin receptor number and insulin receptor phosphorylation, leading to increased insulin sensitivity.
  • the amounts of supplemental chromium shown to have beneficial effects in these studies ranged from 200 to 1000 ⁇ g per day.
  • Steroid-induced diabetes that could not be controlled by oral hypoglycemic medications and/or insulin was also improved to acceptable levels in 47 of 50 people given 600 ⁇ g of chromium as chromium picolinate per day for 2 weeks followed by a daily chromium maintenance dose of 200 ⁇ g (Ravina et al . , Diabetes Med. , supra ; Ravina et al . , 1999, J. Trace Elem. Exptl. Med, supra) . Insulin sensitivity of obese subjects with a family history of diabetes also improved following 1000 ⁇ g daily of supplemental chromium as chromium picolinate (Cefalu et al . , supra) .
  • Blood lipid levels have also been shown to improve following chromium supplementation, with the greatest improvements in total cholesterol, HDL-cholesterol and triglycerides in subjects with the highest initial levels .
  • Chromium picolinate is currently the most widely used, but it is not water soluble, and questions concerning toxicity have been raised (Sterns et al . 1995. FASEB J. vol. 9, pp. 1643-1649).
  • Chromium polynicotinate is a poorly-absorbed mixture of a number of compounds; it is not stable and likely forms insoluble olated chromium polymers. The absorption of chromium from chromium chloride is generally approximately 0.4% (Anderson et al . 1983. J. Nutr.
  • chromium-histidine complex useful as a nutritional supplement and having improved absorption capability over currently available chromium nutritional supplements .
  • It is also an object of the invention to provide a composition comprising the novel chromium-histidine complex and an ingestible carrier.
  • chromium was found to be an essential nutrient when rats fed a Torula yeast-based diet developed impaired glucose tolerance that was reversed by an insulin potentiating factor whose active component was shown to be trivalent chromium (Mertz and Schwarz . 1959. Am. J. Physiol. vol. 196, pp. 614-618; Schwarz and Mertz. 1959. Arch. Biochem. Biophys . vol. 85, pp. 292-295) .
  • the element has subsequently been established as essential for fish, mice, squirrel monkeys, guinea pigs, pigs, cattle and humans (Anderson, supra) .
  • Chromium was administered in the formulations listed in Table 1 at dosages of 200 ⁇ g chromium to three adult males and three females, and absorption during the first 24 hours was measured based on urinary chromium excretion. Results are shown in Table 1 where it can be seen that the novel chromium-histidine complex is absorbed at almost twice the level as that of the closest sample, chromium picolinate.
  • the complex may be prepared as described in Example 1. Complexation results in at least two histidine residues attached to the chromium metal ion, providing a multi-ringed structure. Bonds may be formed between the metal ion and both the carboxyl and amino groups of the amino acid. It is believed that, since histidine contains three nitrogens (as electron donors) as well as a ring component, the possibility of the formation of a number of heterocyclic rings exists, thus forming a multiplex unit.
  • Chromium-histidine compounds may be used for, but are not limited to, improvements in glucose, insulin, cholesterol, HDL- cholesterol, triglycerides and other risks factors associated with diabetes and cardiovascular diseases . These compounds may also improve muscle mass and decrease body fat. Supplements should be of benefit to humans as well as other mammals such as farm animals and pets .
  • ESADDI The Estimated Safe and Adequate Daily Dietary Intake (ESADDI) for chromium for children 7 years to adult is 50 to 200 ⁇ g per day (National Research Council, Recommended Dietary Allowance, 10 th ed., Washington, DC: National Academy Press, 1989).
  • Normal dietary intake of chromium for adults is suboptimal based upon the recommended intakes and studies showing beneficial effects of supplemental chromium.
  • Normal dietary intake of people in the U.S. is approximately 50 to 60% of the minimum suggested minimum daily intake of about 50 ⁇ g (Anderson et al . 1991. In Seventh International Symposium on Trace Elements in Man and Animals. Momcilovic, B., ed. Dubrovnik, pp. 3-6) .
  • Chromium-histidine complexes may be combined with any ingestible carrier for consumption as a tablet, capsule or as a fortificant in foods or food products . Since the complex is water-soluble and stable in aqueous solutions, various aqueous solutions may also be effectively utilized. Acceptable carriers are well-known in the art, and these products may be prepared according to processes well-known to those of skill in the art.
  • a chromium supplement for humans capsules, tablets or their equivalent containing about 100 to about 200 ⁇ g of chromium should be consumed once or twice daily between meals . Maximal beneficial effects of chromium are anticipated to occur at about 400 ⁇ g of chromium as chromium-histidine complex per day or less. It should be noted that, since chromium is the essential nutrient of interest, effective amounts are given in terms of chromium per se rather than in terms of the total complex.
  • chromic acetate or chromic chloride Three-fold molar excess of histidine is added slowly to chromic acetate or chromic chloride in an aqueous solution at 80°C. The solution is then heated an additional 30 min, cooled to approximately room temperature, and the pH adjusted to pH 5 to 5.5 with concentrated ammonium hydroxide. After cooling, sample can be freeze-dried and used as a nutrient supplement.
  • Other amino acids may also be included in the formulation, but at least one molar equivalent of histidine per mole of chromium must be present .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Chromium is an essential element which has been shown to have beneficial effects on carbohydrate and lipid metabolism. Often, dietary intake is suboptimal, and nutritional supplements may not be effective due to poor absorption in the gastrointestinal tract. A novel chromium-histidine complex has been prepared which significantly improves absorption capability over current available chromium nutritional supplements. The complex is safe, easily prepared and may be combined with an ingestible carrier for consumption as a tablet, capsule, aqueous solution, food or food product.

Description

CHROMIUM-HISTIDINE COMPLEXES AS NUTRIENT SUPPLEMENTS
BACKGROUND OF THE INVENTION
1. Field of the Invention.
Chromium, a physiologically important metal, is an essential element required for normal carbohydrate and lipid metabolism. Insufficient amounts may result in improper functioning of the metabolic process and lead to a number of physiological disorders . Membranes of the absorptive cells of the mammalian intestine often present a barrier to effective absorption of chromium, leading to insufficient amounts present in the bloodstream. The present invention relates to a chromium complex having improved absorption capabilities .
2. Description of the Relevant Art .
Normal dietary chromium intake for humans and other mammalians is often suboptimal . Insufficient dietary intake of chromium leads to increases in risk factors associated with diabetes and cardiovascular diseases including elevated circulating insulin, glucose, triglycerides, total cholesterol, reduced HDL-cholesterol and impaired immune function (Anderson, R.A. 1998. J. Am. Coll. Nutr. vol. 17, pp. 548-555) .
The beneficial effects of supplemental chromium on human subjects have been reviewed by Anderson { supra) . There are more than 30 studies reporting beneficial effects on subjects with varying degrees of glucose intolerance, ranging from marginally elevated to overt diabetes. Supplemental chromium has been shown to improve the signs and/or symptoms of diabetes in people with glucose intolerance [Cefalu et al . 1999. J. Trace Elem. Exptl. Med. (In press)] and type 1 (Ravina et al . 1995. J. Trace Elem. Exptl. Med. vol. 8, pp. 183-190), type 2 (Ravina et al . , supra ;
Anderson et al . 1997. Diabetes . vol. 46, pp. 1786-1791), gestational [Jovanovic et al . 1999. J. Trace Elem. Exptl. Med. (In press)] and steroid-induced diabetes [Ravina et al . 1999. Diabetes Med. vol. 16, pp. 164-167; Ravina et al . 1999. J. Trace Elem. Exptl. Med. (In press)] . Chromium also improves insulin function by increasing insulin binding to cells, insulin receptor number and insulin receptor phosphorylation, leading to increased insulin sensitivity. The amounts of supplemental chromium shown to have beneficial effects in these studies ranged from 200 to 1000 μg per day. In the study of Anderson et al . ( supra) involving 180 subjects with type 2 diabetes, chromium effects were greater at 1000 μg per day than at 200 μg per day. The most dramatic improvements were shown in hemoglobin A1C, which is a reliable indicator of long-term glucose control. Hemoglobin A1C in the placebo group was 8.5 ± 0.2%, 7.5 ± 0.2% in the 200-μg group and 6.6 ± 0.1% in the group of subjects receiving 1000 μg of chromium as chromium picolinate per day for 4 months. Improvements in women with gestational diabetes were also greater in the group receiving 8 μg per kg body weight per day compared with those receiving 4 μg per kg body weight (Jovanic et al . , supra) .
Steroid-induced diabetes that could not be controlled by oral hypoglycemic medications and/or insulin was also improved to acceptable levels in 47 of 50 people given 600 μg of chromium as chromium picolinate per day for 2 weeks followed by a daily chromium maintenance dose of 200 μg (Ravina et al . , Diabetes Med. , supra ; Ravina et al . , 1999, J. Trace Elem. Exptl. Med, supra) . Insulin sensitivity of obese subjects with a family history of diabetes also improved following 1000 μg daily of supplemental chromium as chromium picolinate (Cefalu et al . , supra) .
Blood lipid levels have also been shown to improve following chromium supplementation, with the greatest improvements in total cholesterol, HDL-cholesterol and triglycerides in subjects with the highest initial levels .
It is thus clear that normal dietary intake of chromium is often suboptimal and that beneficial effects can be observed following supplementation. The most widely-used supplements are chromium picolinate and chromium polynicotinate . Chromium picolinate is currently the most widely used, but it is not water soluble, and questions concerning toxicity have been raised (Sterns et al . 1995. FASEB J. vol. 9, pp. 1643-1649). Chromium polynicotinate is a poorly-absorbed mixture of a number of compounds; it is not stable and likely forms insoluble olated chromium polymers. The absorption of chromium from chromium chloride is generally approximately 0.4% (Anderson et al . 1983. J. Nutr. vol. 113, pp. 308-311) and from chromium picolinate, currently the most common chromium supplement, approximately 1.2% at intakes up to 1000 μg per day (Campbell et al . 1999. J. Appl . Physiol . vol. 86, pp. 29-30). Chromium incorporation into rat tissues has been shown to vary widely depending upon form (Anderson et al . 1996. J. Trace Elem. Exptl. Med. vol. 9, pp. 11- 25) . The highest concentrations were found in the kidney, followed by liver, spleen, heart, lungs and gastrocnemius muscle. The remaining chromium compounds that are available commercially are largely untested regarding both biological activity and absorption. Additional forms of chromium with improved absorption are urgently needed to help prevent and/or alleviate signs, symptoms and other risk factors associated with diabetes and cardiovascular diseases .
SUMMARY OF THE INVENTION
We have discovered a new form of chromium containing the amino acid histidine, which has surprisingly better absorption than any available chromium-containing compound tested. The complex should pose little or no toxicity, other than that for chromium itself, which is very low. Histidine, an essential amino acid, would be beneficial even at levels several-fold higher than would be present in a nutritional supplement .
In accordance with this discovery, it is an object of the invention to provide a chromium-histidine complex useful as a nutritional supplement and having improved absorption capability over currently available chromium nutritional supplements .
It is also an object of the invention to provide a composition comprising the novel chromium-histidine complex and an ingestible carrier.
Other objects and advantages will become readily apparent from the following description.
DETAILED DESCRIPTION OF THE INVENTION
More than three decades ago chromium was found to be an essential nutrient when rats fed a Torula yeast-based diet developed impaired glucose tolerance that was reversed by an insulin potentiating factor whose active component was shown to be trivalent chromium (Mertz and Schwarz . 1959. Am. J. Physiol. vol. 196, pp. 614-618; Schwarz and Mertz. 1959. Arch. Biochem. Biophys . vol. 85, pp. 292-295) . The element has subsequently been established as essential for fish, mice, squirrel monkeys, guinea pigs, pigs, cattle and humans (Anderson, supra) . The nutritional requirement for chromium in humans was demonstrated during the 1970 's when a patient on total parenteral nutrition developed severe signs of diabetes including weight loss, glucose intolerance and peripheral neuropathy that were refractory to insulin but improved by supplemental chromium (Jeejeebhoy et al . 1977. Am. J. Clin. Nutr. vol. 30, pp. 531-538).
Although chromium as a dietary supplement has been available for some time, problems of administration have persisted apparently due to a lack of absorption in the gastrointestinal tract. Without adequate absorption, the element cannot be distributed to those sites in the body which would effectively utilize it.
Amino acid-chromium complexes using other amino acids had previously been disclosed (Abdel-Monem, Pat. No. 3,925,433, December 9, 1975; Ashmead et al . , Pat. No. 4,863,989, September 5, 1989; Ridenour, Pat. No. 5,702,718, December 30, 1997; Ashmead et al., Pat. No. 5,614,553, March 25, 1997; Anderson et al . , 1996, supra) , however, none had studied the relative effectiveness of chromium-histidine complexes in human absorption. Experiments were carried out to investigate the efficacy of chromium-histidine complexes in the absorption process . Chromium was administered in the formulations listed in Table 1 at dosages of 200 μg chromium to three adult males and three females, and absorption during the first 24 hours was measured based on urinary chromium excretion. Results are shown in Table 1 where it can be seen that the novel chromium-histidine complex is absorbed at almost twice the level as that of the closest sample, chromium picolinate.
The complex may be prepared as described in Example 1. Complexation results in at least two histidine residues attached to the chromium metal ion, providing a multi-ringed structure. Bonds may be formed between the metal ion and both the carboxyl and amino groups of the amino acid. It is believed that, since histidine contains three nitrogens (as electron donors) as well as a ring component, the possibility of the formation of a number of heterocyclic rings exists, thus forming a multiplex unit.
Table 1. Absorption of Chromium Compounds .
Figure imgf000006_0001
Chromium absorbed the first 24 hours following intake of 200 μg of chromium in the various complexes listed, based on urinary chromium excretion (3 adult males and 3 females) . a,b,c,d,e Nu kg-rj-g with different superscripts are significantly different at p<0.05 using Duncan=s Multiple Range Test (SAS Institute, Cary, NC) .
Chromium-histidine compounds may be used for, but are not limited to, improvements in glucose, insulin, cholesterol, HDL- cholesterol, triglycerides and other risks factors associated with diabetes and cardiovascular diseases . These compounds may also improve muscle mass and decrease body fat. Supplements should be of benefit to humans as well as other mammals such as farm animals and pets .
The Estimated Safe and Adequate Daily Dietary Intake (ESADDI) for chromium for children 7 years to adult is 50 to 200 μg per day (National Research Council, Recommended Dietary Allowance, 10th ed., Washington, DC: National Academy Press, 1989). Normal dietary intake of chromium for adults is suboptimal based upon the recommended intakes and studies showing beneficial effects of supplemental chromium. Normal dietary intake of people in the U.S. is approximately 50 to 60% of the minimum suggested minimum daily intake of about 50 μg (Anderson et al . 1991. In Seventh International Symposium on Trace Elements in Man and Animals. Momcilovic, B., ed. Dubrovnik, pp. 3-6) .
Chromium-histidine complexes may be combined with any ingestible carrier for consumption as a tablet, capsule or as a fortificant in foods or food products . Since the complex is water-soluble and stable in aqueous solutions, various aqueous solutions may also be effectively utilized. Acceptable carriers are well-known in the art, and these products may be prepared according to processes well-known to those of skill in the art. As a chromium supplement for humans, capsules, tablets or their equivalent containing about 100 to about 200 μg of chromium should be consumed once or twice daily between meals . Maximal beneficial effects of chromium are anticipated to occur at about 400 μg of chromium as chromium-histidine complex per day or less. It should be noted that, since chromium is the essential nutrient of interest, effective amounts are given in terms of chromium per se rather than in terms of the total complex.
EXAMPLES
Example 1. Synthesis of Histidine Complexes .
Three-fold molar excess of histidine is added slowly to chromic acetate or chromic chloride in an aqueous solution at 80°C. The solution is then heated an additional 30 min, cooled to approximately room temperature, and the pH adjusted to pH 5 to 5.5 with concentrated ammonium hydroxide. After cooling, sample can be freeze-dried and used as a nutrient supplement. Other amino acids may also be included in the formulation, but at least one molar equivalent of histidine per mole of chromium must be present .

Claims

We claim :
1. A chromium-histidine complex effective for improving the absorption of chromium in mammals.
2. A composition comprising a chromium-histidine complex in an amount effective for improving the absorption of chromium in mammals and an ingestible carrier.
3. The composition of claim 2, wherein said effective amount of chromium-histidine is from about 50 μg to about 1000 μg of chromium .
4. The composition of claim 3, wherein said effective amount of chromium-histidine is from about 100 μg to about 400 μg of chromium.
5. The composition of claim 4, wherein said effective amount of chromium-histidine is from about 100 μg to about 200 μg of chromium .
6. The composition of claim 2, wherein said composition is in the form of a tablet, a capsule, an aqueous solution, a food or a food product .
PCT/US2000/027727 1999-10-08 2000-10-06 Chromium-histidine complexes as nutrient supplements WO2001027123A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00970641A EP1235835B1 (en) 1999-10-08 2000-10-06 Chromium-histidine complexes as nutrient supplements
CA002386790A CA2386790C (en) 1999-10-08 2000-10-06 Chromium-histidine complexes as nutrient supplements
JP2001530341A JP4837214B2 (en) 1999-10-08 2000-10-06 Chromium-histidin complex as a nutritional supplement
DK00970641T DK1235835T3 (en) 1999-10-08 2000-10-06 Chromium-histidine complexes as nutritional supplements
DE60032509T DE60032509T2 (en) 1999-10-08 2000-10-06 CHROMI-HISTIDINE COMPLEXES AS FOOD ADDITIVES
AU79990/00A AU779042B2 (en) 1999-10-08 2000-10-06 Chromium-histidine complexes as nutrient supplements
MXPA02003459A MXPA02003459A (en) 1999-10-08 2000-10-06 Chromium histidine complexes as nutrient supplements.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/414,645 1999-10-08
US09/414,645 US6689383B1 (en) 1999-10-08 1999-10-08 Chromium-histidine complexes as nutrient supplements

Publications (1)

Publication Number Publication Date
WO2001027123A1 true WO2001027123A1 (en) 2001-04-19

Family

ID=23642324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027727 WO2001027123A1 (en) 1999-10-08 2000-10-06 Chromium-histidine complexes as nutrient supplements

Country Status (13)

Country Link
US (1) US6689383B1 (en)
EP (1) EP1235835B1 (en)
JP (1) JP4837214B2 (en)
AT (1) ATE348834T1 (en)
AU (1) AU779042B2 (en)
CA (1) CA2386790C (en)
CY (1) CY1107547T1 (en)
DE (1) DE60032509T2 (en)
DK (1) DK1235835T3 (en)
ES (1) ES2277857T3 (en)
MX (1) MXPA02003459A (en)
PT (1) PT1235835E (en)
WO (1) WO2001027123A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121312A2 (en) * 2006-04-12 2007-10-25 Interhealth Nutraceuticals, Inc. Trivalent chromium compounds, compositions and methods of use
WO2016209812A1 (en) * 2015-06-23 2016-12-29 Jds Therapeutics, Llc Chromium histidinate and chromium picolinate complexes
US9597404B2 (en) 2007-03-13 2017-03-21 Jds Therapeutics, Llc Methods and compositions for sustained release of chromium
US11857553B2 (en) 2016-02-11 2024-01-02 Nutrition21, LLC Chromium containing compositions for improving health and fitness

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247328B2 (en) * 2002-05-31 2007-07-24 Zinpro Corporation Chromium (III) alpha amino acid complexes
US20060029642A1 (en) * 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
US7271278B2 (en) * 2005-06-28 2007-09-18 The University Of Wyoming Application of chromium-amino acid complexes in the treatment of diabetes and other diseases
CA3021932C (en) * 2007-01-31 2020-12-15 Jds Therapeutics, Llc Use of chromium histidinate for treatment of cardiometabolic disorders
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
WO2012119007A1 (en) 2011-03-01 2012-09-07 N21 Acquisition Holding, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US10820617B1 (en) 2018-03-29 2020-11-03 Government Of The United States, As Represented By The Secretary Of The Air Force All inclusive electrolytes, vitamins, and protein powder training supplement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925433A (en) * 1973-09-10 1975-12-09 Zinpro Corp 1:1 And 2:1 chromium, alpha amino acid complex salts
US4167564A (en) * 1974-09-23 1979-09-11 Albion Laboratories, Inc. Biological assimilation of metals
US5614553A (en) * 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ183858A (en) * 1976-12-17 1979-10-25 Ashmead Hh Polyvalent metal proteinates as food additives
US4863898A (en) 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4830716B1 (en) 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US5702718A (en) 1995-07-25 1997-12-30 K.E.R. Associates, Inc. Method for applying metal-amino acid complexes as supplements to feed

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925433A (en) * 1973-09-10 1975-12-09 Zinpro Corp 1:1 And 2:1 chromium, alpha amino acid complex salts
US4167564A (en) * 1974-09-23 1979-09-11 Albion Laboratories, Inc. Biological assimilation of metals
US5614553A (en) * 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007121312A2 (en) * 2006-04-12 2007-10-25 Interhealth Nutraceuticals, Inc. Trivalent chromium compounds, compositions and methods of use
WO2007121312A3 (en) * 2006-04-12 2008-05-15 Interhealth Nutraceuticals Inc Trivalent chromium compounds, compositions and methods of use
US9700546B2 (en) 2006-04-12 2017-07-11 Interhealth Nutraceuticals, Inc. Trivalent chromium compounds, compositions and methods of use
US10245325B2 (en) 2007-03-13 2019-04-02 Jds Therapeutics, Llc Methods and compositions for the sustained release of chromium
US9597404B2 (en) 2007-03-13 2017-03-21 Jds Therapeutics, Llc Methods and compositions for sustained release of chromium
US9675702B2 (en) 2007-03-13 2017-06-13 Jds Therapeutics, Llc Methods and compositions for the sustained release of chromium
GB2556247A (en) * 2015-06-23 2018-05-23 Jds Therapeutics Llc Chromium histidinate and chromium picolinate complexes
WO2016209812A1 (en) * 2015-06-23 2016-12-29 Jds Therapeutics, Llc Chromium histidinate and chromium picolinate complexes
GB2556247B (en) * 2015-06-23 2021-03-03 Jds Therapeutics Llc Chromium histidinate and chromium picolinate complexes
GB2587289A (en) * 2015-06-23 2021-03-24 Jds Therapeutics Llc Chromium histidinate and chromium picolinate complexes
GB2587289B (en) * 2015-06-23 2021-06-23 Jds Therapeutics Llc Chromium Histidinate Complexes
US11857553B2 (en) 2016-02-11 2024-01-02 Nutrition21, LLC Chromium containing compositions for improving health and fitness
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness

Also Published As

Publication number Publication date
JP2003516935A (en) 2003-05-20
EP1235835A4 (en) 2004-09-22
AU7999000A (en) 2001-04-23
ES2277857T3 (en) 2007-08-01
JP4837214B2 (en) 2011-12-14
EP1235835A1 (en) 2002-09-04
DE60032509D1 (en) 2007-02-01
CA2386790C (en) 2009-07-14
CA2386790A1 (en) 2001-04-19
CY1107547T1 (en) 2013-03-13
AU779042B2 (en) 2005-01-06
MXPA02003459A (en) 2002-08-20
DE60032509T2 (en) 2007-10-11
US6689383B1 (en) 2004-02-10
PT1235835E (en) 2007-01-31
EP1235835B1 (en) 2006-12-20
DK1235835T3 (en) 2007-02-12
ATE348834T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
Golden et al. Effect of zinc supplementation on the dietary intake, rate of weight gain, and energy cost of tissue deposition in children recovering from severe malnutrition
Sandström et al. Zinc absorption from composite meals II. Influence of the main protein source
US4315927A (en) Dietary supplementation with essential metal picolinates
US7445803B2 (en) Chromium (III) alpha amino acid complexes
US5614553A (en) Composition and method for alleviating stress in warm-blooded animals
US6689383B1 (en) Chromium-histidine complexes as nutrient supplements
US5888553A (en) Non-steroidal anabolic composition
EP0825861B1 (en) High-dose chromic tripicolinate for the treatment of type ii diabetes
KR20040044455A (en) Nutritional compositions for controlling blood glucose level
USRE33988E (en) Dietary supplementation with essential metal picolinates
JP3907098B2 (en) Nutritional drink or jelly
US6004926A (en) Body fat percent-lowering, body composition-improving food composition and a method for lowering the body fat percentage and improving the body composition
AU2549201A (en) Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
Oski et al. Anemia due to inadequate iron sources or poor iron utilization
EP1393738A1 (en) Drugs for diabetes
JPH0662798A (en) Food for low-glucose-tolerant man
MAK et al. The effect of a low protein diet with amino acid/keto acid supplements on glucose metabolism in children with uremia
JP2002121134A (en) Use of lipoic acid for improving bioavailability of mineral salt
JP3618774B2 (en) Composition for the treatment of iron deficiency anemia
Anderson et al. Chromium-histidine complexes as nutrient supplements
Kenny et al. Clinical zinc deficiency during adequate enteral nutrition.
Johnson Influence of ascorbic acid, zinc, iron, sucrose and fructose on copper status
EP0363337A1 (en) Energy substrate containing hydroxycarboxylic acid
JP2000264844A (en) Nutritive composition for kidney disease patient
Kopple Nutrition and the kidney

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2001 530341

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003459

Country of ref document: MX

Ref document number: 2386790

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000970641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 79990/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000970641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 79990/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000970641

Country of ref document: EP